Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome

Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a t...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kraaij, Tom DA, Mostard, Rémy LM, Ramiro, Sofia, Magro Checa, Cesar, van Dongen, Christel MP, van Haren, Eric HJ, Buijs, Jacqueline, Landewé, Robert BM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213824/
https://www.ncbi.nlm.nih.gov/pubmed/32399455
http://dx.doi.org/10.12890/2020_001675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213824/
https://www.ncbi.nlm.nih.gov/pubmed/32399455
http://dx.doi.org/10.12890/2020_001675

Ejemplares similares